SLI-RX-BET MID dose clinical trials

Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy

This study is looking for better ways to treat birch pollen allergy. It tests different doses of a new medicine, given under the tongue, to see if it can reduce symptoms like sneezing and itchy eyes during pollen season.